Edition:
United Kingdom

Julie Steenhuysen

Trump puts on a few pounds, enters obese range: medical report

15 Feb 2019

WASHINGTON/CHICAGO U.S. President Donald Trump has gained weight over the past year and is now in the obese range, although he remains in "very good health overall," according to results of an annual presidential physical examination conducted last week. | Video

UPDATE 2-Trump puts on a few pounds, enters obese range -medical report

14 Feb 2019

WASHINGTON/CHICAGO, Feb 14 U.S. President Donald Trump has gained weight over the past year and is now in the obese range, although he remains in "very good health overall," according to results of an annual presidential physical examination conducted last week.

Gilead misses key goal in NASH liver disease trial, shares sink

11 Feb 2019

CHICAGO Gilead Sciences Inc said on Monday that a late-stage study of a key experimental drug aimed at treating NASH, a progressive fatty liver disease, failed to meet its main goal, sending the company's shares down 4.6 percent in after-hours trading.

J&J becomes first drugmaker to add prices to television ads

07 Feb 2019

CHICAGO Johnson & Johnson said on Thursday it will start adding the price of its medicines to television commercials by next month, becoming the first drugmaker to heed a call by U.S. President Donald Trump for price transparency of drugs advertised directly to consumers on TV.

Prior dengue infection may protect against Zika: study

07 Feb 2019

CHICAGO Prior infection with dengue, a mosquito-borne disease that infects nearly 400 million people a year, could reduce the risk of contracting Zika nearly by half, U.S. and Brazilian researchers reported on Thursday.

Undeterred by Sanofi's stumble, Takeda takes similar path with dengue shot

30 Jan 2019

CHICAGO A new vaccine for the dengue virus is taking a potentially risky road to prevent the mosquito-borne disease that infects nearly 400 million people each year.

RPT-FOCUS-Bypassing U.S. regulators, Takeda takes its dengue shot to the tropics

30 Jan 2019

CHICAGO, Jan 30 A new vaccine for the dengue virus is taking a potentially risky road to prevent the mosquito-borne disease that infects nearly 400 million people each year.

Undeterred by Sanofi's stumble, Takeda takes similar path with dengue shot

30 Jan 2019

CHICAGO A new vaccine for the dengue virus is taking a potentially risky road to prevent the mosquito-borne disease that infects nearly 400 million people each year.

RPT-FOCUS-Undeterred by Sanofi's stumble, Takeda takes similar path with dengue shot

30 Jan 2019

CHICAGO, Jan 30 A new vaccine for the dengue virus is taking a potentially risky road to prevent the mosquito-borne disease that infects nearly 400 million people each year.

Takeda dengue vaccine meets main goal of trial; detailed results to come

29 Jan 2019

CHICAGO Takeda Pharmaceutical Co said on Tuesday that its experimental dengue vaccine appears to be safe and effective at preventing all four types of the mosquito-borne disease, meeting the main goal of the Japanese drugmaker's late-stage clinical trial.

World News